SCHEMBL2564673

SCHEMBL2564673

CCC(C)c1ccc(NC(=O)c2ccc(F)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.60
NPC1 O15118 6/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
NPSR1 Q6W5P4 2/20 0.60
ALDH1A1 P00352 2/20 0.60
TP53 P04637 1/20 0.60
PTPN1 P18031 1/20 0.59
MITF O75030 1/20 0.58
ATM Q13315 1/20 0.57
TSHR P16473 1/20 0.56
MAPT P10636 1/20 0.56
NFKB1 P19838 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56
POLB P06746 3/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
TDP1 Q9NUW8 1/20 0.54
HTT P42858 1/20 0.54
SNCA P37840 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12218430 0.87 NPC1 (0.67) RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1
SCHEMBL2564961 0.85 NPC1 (0.71) RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1
SCHEMBL825718 0.85 NPC1 (0.63) RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1
SCHEMBL17660220 0.84 PTPN1 (0.67) RAB9ANPC1SMN1; SMN2ALDH1A1PTPN1
SCHEMBL7299664 0.84 NR1H4 (0.68) RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1
SCHEMBL2564458 0.83 RAB9A (0.62) RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1
SCHEMBL4182502 0.82 ROCK2 (0.68) RAB9ANPC1SMN1; SMN2TP53PTPN1
SCHEMBL4182497 0.82 ROCK2 (0.68) RAB9ANPC1SMN1; SMN2TP53PTPN1
SCHEMBL12630758 0.82 MEN1 (0.57) RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1
SCHEMBL13851187 0.82 NPC1 (0.56) RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2382194-A2 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE RESVERLOGIX CORP. (CA) 2011-11-02 EP disclosed